These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15142135)

  • 1. Cognitive effects of hormonal treatment for prostate cancer.
    Koupparis A; Ramsden A; Persad R
    BJU Int; 2004 May; 93(7):915-6. PubMed ID: 15142135
    [No Abstract]   [Full Text] [Related]  

  • 2. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.
    Jenkins VA; Bloomfield DJ; Shilling VM; Edginton TL
    BJU Int; 2005 Jul; 96(1):48-53. PubMed ID: 15963119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? results from a pilot study.
    Crook TJ; Bramble J
    BJU Int; 2005 Oct; 96(6):918; author reply 918-9. PubMed ID: 16153235
    [No Abstract]   [Full Text] [Related]  

  • 4. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
    Green HJ; Pakenham KI; Headley BC; Yaxley J; Nicol DL; Mactaggart PN; Swanson CE; Watson RB; Gardiner RA
    BJU Int; 2004 May; 93(7):975-9. PubMed ID: 15142146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Castration of prostate cancer patients and cognition].
    Portin R; Koskinen A; Helenius H; Nurmi M; Salminen E
    Duodecim; 2005; 121(16):1784-5. PubMed ID: 16268226
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.
    Mottet N; Prayer-Galetti T; Hammerer P; Kattan MW; Tunn U
    BJU Int; 2006 Jul; 98(1):20-7. PubMed ID: 16566812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer.
    Barrass BJ; Thurairaja R; Persad RA
    BJU Int; 2004 Jun; 93(9):1175-6. PubMed ID: 15180599
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer.
    Nakabayashi M; Bartlett RA; Oh WK
    J Clin Oncol; 2006 Jun; 24(18):2958-9. PubMed ID: 16782932
    [No Abstract]   [Full Text] [Related]  

  • 9. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 11. Hot flashes in prostate cancer: state of the science.
    Engstrom CA
    Am J Mens Health; 2008 Jun; 2(2):122-32. PubMed ID: 19477776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing complications of androgen deprivation therapy for prostate cancer.
    Holzbeierlein JM
    Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the use of histrelin acetate in the treatment of prostate cancer.
    Crawford ED
    BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
    Whelan P
    Eur Urol; 2008 Oct; 54(4):823-4. PubMed ID: 18243509
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 16. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
    Collins B; Mackenzie J; Stewart A; Bielajew C; Verma S
    Psychooncology; 2009 Aug; 18(8):811-21. PubMed ID: 19085975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma.
    Wiechert A; Tüting T; Bieber T; Haidl G; Wenzel J
    Br J Dermatol; 2008 Jul; 159(1):231-3. PubMed ID: 18476960
    [No Abstract]   [Full Text] [Related]  

  • 18. The developing role of hormonal therapy in the treatment of prostate cancer.
    Abrahamsson PA
    BJU Int; 2009 Mar; 103 Suppl 2():1. PubMed ID: 19228145
    [No Abstract]   [Full Text] [Related]  

  • 19. [And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)].
    Miller K
    MMW Fortschr Med; 2009 Jul; 151(30-33):72-3. PubMed ID: 19722471
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
    Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.